BIOMAT Database Logo BIOMAT Database Logo

Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. 1997

M Shimura, and H Wada, and Y Wakita, and T Nakase, and K Hiyoyama, and S Nagaya, and Y Mori, and H Shiku
Second Department of Internal Medicine, Mie University School of Medicine, Tsu-city, Mie-ken, Japan.

We measured the plasma levels of tissue factor (TF) and tissue factor pathway inhibitor (TFPI) in patients with disseminated intravascular coagulation (DIC) to examine the relationship between TFPI and vascular endothelial cell injury. Plasma TF (273 +/- 90 pg/ml) and TFPI (252 +/- 125 ng/ml) levels were significantly increased in patients with DIC compared with non-DIC patients. Plasma TF antigen level was significantly increased in pre-DIC patients (285 +/- 85 pg/ml), while the plasma TFPI level (152 +/- 54 ng/ml) was not markedly increased in such a state. The plasma TF/TFPI ratio was high in the pre-DIC patients (2.10 +/- 0.90), and low in the DIC patients (1.40 +/- 0.87) and healthy volunteers (0.84 +/- 0.26). There was no significant difference between the DIC patients with a good outcome and those with a poor outcome in terms of plasma TF levels, although the plasma TFPI level in the DIC patients with a good outcome (289 +/- 133 ng/ml) was significantly higher than those with a poor outcome (187 +/- 75 ng/ml). During the clinical course of DIC, plasma TF antigen was increased first, and an increase of the plasma TFPI level followed the increase in plasma TF level. These findings suggest that plasma TFPI is released from vascular endothelial cells and it may reflect vascular endothelial cell injury. It is conceivable that TF and TFPI may play an important role in the onset of DIC.

UI MeSH Term Description Entries
D008074 Lipoproteins Lipid-protein complexes involved in the transportation and metabolism of lipids in the body. They are spherical particles consisting of a hydrophobic core of TRIGLYCERIDES and CHOLESTEROL ESTERS surrounded by a layer of hydrophilic free CHOLESTEROL; PHOSPHOLIPIDS; and APOLIPOPROTEINS. Lipoproteins are classified by their varying buoyant density and sizes. Circulating Lipoproteins,Lipoprotein,Lipoproteins, Circulating
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D004211 Disseminated Intravascular Coagulation A disorder characterized by procoagulant substances entering the general circulation causing a systemic thrombotic process. The activation of the clotting mechanism may arise from any of a number of disorders. A majority of the patients manifest skin lesions, sometimes leading to PURPURA FULMINANS. Consumption Coagulopathy,Coagulation, Disseminated Intravascular,Disseminated Coagulation, Intravascular,Intravascular Coagulation, Disseminated,Intravascular Disseminated Coagulation,Coagulation, Intravascular Disseminated,Coagulations, Disseminated Intravascular,Coagulations, Intravascular Disseminated,Coagulopathies, Consumption,Coagulopathy, Consumption,Consumption Coagulopathies,Disseminated Coagulations, Intravascular,Disseminated Intravascular Coagulations,Intravascular Coagulations, Disseminated,Intravascular Disseminated Coagulations
D004730 Endothelium, Vascular Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components. Capillary Endothelium,Vascular Endothelium,Capillary Endotheliums,Endothelium, Capillary,Endotheliums, Capillary,Endotheliums, Vascular,Vascular Endotheliums
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000925 Anticoagulants Agents that prevent BLOOD CLOTTING. Anticoagulant Agent,Anticoagulant Drug,Anticoagulant,Anticoagulant Agents,Anticoagulant Drugs,Anticoagulation Agents,Indirect Thrombin Inhibitors,Agent, Anticoagulant,Agents, Anticoagulant,Agents, Anticoagulation,Drug, Anticoagulant,Drugs, Anticoagulant,Inhibitors, Indirect Thrombin,Thrombin Inhibitors, Indirect
D013925 Thromboplastin Constituent composed of protein and phospholipid that is widely distributed in many tissues. It serves as a cofactor with factor VIIa to activate factor X in the extrinsic pathway of blood coagulation. Antigens, CD142,CD142 Antigens,Coagulation Factor III,Factor III,Tissue Factor,Tissue Thromboplastin,Blood Coagulation Factor III,Coagulin,Glomerular Procoagulant Activity,Prothrombinase,Tissue Factor Procoagulant,Urothromboplastin,Activity, Glomerular Procoagulant,Factor III, Coagulation,Procoagulant Activity, Glomerular,Procoagulant, Tissue Factor,Thromboplastin, Tissue

Related Publications

M Shimura, and H Wada, and Y Wakita, and T Nakase, and K Hiyoyama, and S Nagaya, and Y Mori, and H Shiku
Increased plasma levels of tissue factor pathway inhibitor-activated factor X complex in patients with disseminated intravascular coagulation.
November 2000, American journal of hematology,
M Shimura, and H Wada, and Y Wakita, and T Nakase, and K Hiyoyama, and S Nagaya, and Y Mori, and H Shiku
Plasma tissue factor pathway inhibitor in disseminated intravascular coagulation: comparison of its behavior with plasma tissue factor.
November 1995, Thrombosis research,
M Shimura, and H Wada, and Y Wakita, and T Nakase, and K Hiyoyama, and S Nagaya, and Y Mori, and H Shiku
Elevated levels of tissue factor pathway inhibitor in acute non-lymphoblastic leukemia patients with disseminated intravascular coagulation.
January 1997, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis,
M Shimura, and H Wada, and Y Wakita, and T Nakase, and K Hiyoyama, and S Nagaya, and Y Mori, and H Shiku
Tissue factor in plasma of patients with disseminated intravascular coagulation.
August 1994, American journal of hematology,
M Shimura, and H Wada, and Y Wakita, and T Nakase, and K Hiyoyama, and S Nagaya, and Y Mori, and H Shiku
[Tissue factor pathway in disseminated intravascular coagulation].
May 1999, [Rinsho ketsueki] The Japanese journal of clinical hematology,
M Shimura, and H Wada, and Y Wakita, and T Nakase, and K Hiyoyama, and S Nagaya, and Y Mori, and H Shiku
The tissue factor pathway in disseminated intravascular coagulation.
December 2001, Seminars in thrombosis and hemostasis,
M Shimura, and H Wada, and Y Wakita, and T Nakase, and K Hiyoyama, and S Nagaya, and Y Mori, and H Shiku
[Plasma factor VII levels in disseminated intravascular coagulation].
July 1991, Rinsho byori. The Japanese journal of clinical pathology,
M Shimura, and H Wada, and Y Wakita, and T Nakase, and K Hiyoyama, and S Nagaya, and Y Mori, and H Shiku
Elevated plasma tissue factor antigen level in patients with disseminated intravascular coagulation.
March 1994, American journal of hematology,
M Shimura, and H Wada, and Y Wakita, and T Nakase, and K Hiyoyama, and S Nagaya, and Y Mori, and H Shiku
Expression of tissue factor and tissue factor pathway inhibitor in rats lungs with lipopolysaccharide-induced disseminated intravascular coagulation.
December 1997, Laboratory investigation; a journal of technical methods and pathology,
M Shimura, and H Wada, and Y Wakita, and T Nakase, and K Hiyoyama, and S Nagaya, and Y Mori, and H Shiku
Tissue factor pathway inhibitor (TFPI) in disseminated intravascular coagulation: low levels of the activated factor X-TFPI complex.
October 2000, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis,
Copied contents to your clipboard!